NCT07631182 Action Observation Therapy in Chronic Stroke Via Telerehabilitation
| NCT ID | NCT07631182 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Karabuk University |
| Condition | Chronic Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-06-15 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-06-15 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Stroke, a leading cause of disability worldwide, particularly affects upper extremity function, rendering individuals dependent on others for daily living activities and reducing their quality of life. To mitigate these effects, Action Observation Therapy (AOT), which has gained prominence in recent years, activates the mirror neuron system, triggering learning processes in the motor cortex and supporting functional recovery through the imitation of observed movements. Furthermore, telerehabilitation offers a significant advantage in facilitating access to rehabilitation services for these patients requiring long-term treatment, eliminating barriers such as transportation and cost. The absence of studies in the literature comparing the effectiveness of combining these two methods on hand skills and quality of life in individuals with chronic stroke with conventional physiotherapy makes investigating the clinical value of this approach academically unique and necessary.
Eligibility Criteria
Inclusion Criteria: * Being over 18 years of age, * Diagnosis of left hemiparetic stroke, * Having passed between 6 months since the onset of stroke, * Being in stage 4 or 5 of the hand and stage 4, 5 or 6 of the upper extremity according to Brunnstrom staging, * Being able to sit on a chair for 30 minutes without support (patients who scored 20 or more points in total from the Trunk Impairment Scale), * Scoring 24 or more points from the Mini Mental Test Exclusion Criteria: * Unwillingness to participate in the study, * Having spasticity that prevents grasping and releasing an object (levels 3 and 4 on the Modified Ashworth Scale), * Having a contracture in any of the affected upper extremity joints, * Having severe neglect disorder (scoring 21 or higher on the Catherine Bergego Scale), * Having impaired cooperation, compliance, and behavior during the administration of tests used to obtain data, * Having a mental impairment that prevents communication and following basic commands (scoring less than 24 on the Mini-Mental Test), * Having additional neurological and/or orthopedic problems that may affect motor performance and sitting balance, * Having severe visual and hearing problems (if any, these problems not corrected with assistive devices such as glasses, contact lenses, hearing aids, etc.)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07631182 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07631182 currently recruiting?
Yes, NCT07631182 is actively recruiting participants. Contact the research team at mustafakavak@karabuk.edu.tr for enrollment information.
Where is the NCT07631182 trial being conducted?
This trial is being conducted at Karabük, Turkey (Türkiye), Karabük, Turkey (Türkiye).
Who is sponsoring the NCT07631182 clinical trial?
NCT07631182 is sponsored by Karabuk University. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.